Revolution Medicines Reports Unprecedented Phase 3 Success for Pancreatic Cancer Treatment

Revolution Medicines announced that its daily oral medication, daraxonrasib, met all primary and secondary endpoints in a Phase 3 trial for patients with progressed pancreatic cancer. The results demonstrate a significant improvement in overall survival compared to standard chemotherapy, marking a potential shift in the treatment of one of the most aggressive forms of cancer. Pancreatic cancer is characterized by a low five-year survival rate of approximately 13%. Daraxonrasib targets RAS mutations, which drive tumor growth and are present in roughly 90% of pancreatic cancer cases. This targeted approach offers a potential alternative to the cytotoxic intravenous chemotherapy that has historically been the exclusive treatment option. Clinical data revealed that patients treated with daraxonrasib had a median survival of 13.2 months, compared to 6.7 months for those receiving chemotherapy. This 6.5-month increase represents a 60% reduction in the risk of death. CEO Mark Goldsmith described the outcomes as practice-changing and unprecedented for a Phase 3 trial in this indication. Following the release of the data, shares of Revolution Medicines jumped more than 30%. The company intends to utilize a Commissioner's National Priority Voucher to seek FDA approval, a mechanism that could accelerate the review process to a matter of months. The drug showed a manageable safety profile, although rash was noted as a known side effect. While the current application focuses on second-line treatment for patients whose cancer has spread, the company is also conducting a Phase 3 trial for newly diagnosed patients.